Mucinous ovarian cancer: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Early / localised	1
Second line	1
Other settings	1

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Early stage	Unilateral salpingo-oophorectomy or hysterectomy with staging; appendicectomy if abnormal; chemotherapy usually omitted for stage IA and IB.	Ovarian cancer		-

Second line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Advanced or recurrent	Cytoreduction; carboplatin-paclitaxel or gastrointestinal-type capecitabine-oxaliplatin; trastuzumab for HER2-amplified tumours in trials.	CapecitabineOxaliplatinTrastuzumabCarboplatin		90

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Young women with stage IA disease	Fertility-sparing unilateral salpingo-oophorectomy with staging and close follow-up.	Ovarian cancer		-

Sequence and caution pairings

CautionApproved

Caution: DXd ADC + agents with pneumonitis risk

Enhertu and its DXd cousins can inflame the lungs; combining them with immunotherapy, radiation, or mTOR inhibitors stacks that risk.

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.